DAT (chemotherapy)


DAT in the context of chemotherapy is an acronym that means a chemotherapy regimen most often used as an induction regimen in acute myelogenous leukemia, usually for those who are refractory to the standard "7+3" induction regimen or who has relapsed. But this regimen also can be used as primary, first-line induction therapy.
The DAT regimen consists of:
  1. 'aunorubicin - an anthracycline antibiotic that is able to intercalate DNA, thus disrupting cell division and preventing mitosis;
  2. 'ra-C - an antimetabolite;
  3. hioguanine - another antimetabolite.

    Dosing regimen